


STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

Docket No.
3157.00011

In Re Application Of:
Constance John, et al.



Application No.
10/726,198

Filing Date
12-02-03

Examiner

Customer No.
48924

Group Art Unit
1614

Confirmation No.

Invention:

SUSTAINED RELEASE N-TERMINALLY TRUNCATED GALECTIN-3 AND ANTIBODIES TO GALECTIN-3
CARBOHYDRATE LIGANDS FOR USE IN TREATING DISEASE

COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Signature

Dated: 2-24-05

Kenneth I. Kohn, Reg. No. 30,955
KOHN & ASSOCIATES, PLLC
30500 Northwestern Highway, Suite 410
Farmington Hills, Michigan 48334
(248) 539-5050

Certificate of Mailing by First Class Mail

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

2-24-05


(Date)

Signature of Person Mailing Correspondence

Connie Herty

Typed or Printed Name of Person Mailing Correspondence

CC:



MANUAL OF PATENT EXAMINING PROCEDURE

PTO/SB/08 (2-92)
Sheet 1 of 1

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>			Docket Number (Optional) 10/726,198		Application Number 3157.00011	
			Applicant Constance M. John, et al.			
			Filing Date 12-2-03		Group Art Unit 1614	
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2002/0019009 A1	14.02.02	Roggen, et al.			
FOREIGN PATENT DOCUMENTS						
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS <i>(Including Author, Title, Date Pertinent Pages, Etc.)</i>						
	Gong, Hua Chang, et al., "The NH ₂ Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells," <i>Cancer Research</i> , 59:6239-6245 (1999).					
	Pelletier, et al., "Specific Recognition and Cleavage of Galectin-3 by Leishmania major through Species-specific Polygalactose Epitope," <i>J. Biol. Chem.</i> 277:17663-17670 (2002).					
	Database Medline on Dialog, Medline Acc. No. 14950774, Constance, et al., "Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer, <i>Clin. Cancer Res.</i> ; 9:2374-83 (2003).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.						

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE